GENERAL ENQUIRIES: Tel: + 27 12 841 2911 | Email: callcentre@csir.co.za

Browsing by Author "Semete, B"

Sort by: Order: Results:

  • Semete, B; Booysen, L; Kalombo, Lonji; Ramalapa, B; Hayeshi, R; Swai, HS (Elsevier, 2012-03)
    The surface of nanoparticles is often functionalised with polymeric surfactants, in order to increase systemic circulation time. This has been investigated mainly for intravenously administered nanoparticles. This study ...
  • Swai, H; Hillie, KT; Cingo, N; Kalombo, Lonji; Legodi, M; Semete, B (2006-02)
    In this study, isoniazid, one of the most potent anti-TB drugs, was successfully encapsulated in poly (D, L- lactide-co-glycolide) (PLG) and in alginate-chitosan polymeric systems using a double-emulsion method and a ...
  • Semete, B; Booysen, L; Lemmer, Yolandy; Kalombo, Lonji; Katata, L; Verschoor, J; Swai, HS (Elsevier, 2010-10)
    The remarkable physicochemical properties of particles in the nanometer range have been proven to address many challenges in the field of science. However, the possible toxic effects of these particles have raised some ...
  • Lemmer, Yolandy; Semete, B; Kalombo, Lonji; Ramalapa, B; Jones, AT; Swai, HS; Verschoor, JA (CSIR, 2010-09-01)
    Challenges in treatment of Tuberculosis (TB) include non-specific localisation of the drugs which results in too low concentrations of the drugs reaching the target site of infection, thus leading to reduced effectiveness. ...
  • Benadie, Y; Semete, B; Venter, L; Kalombo, Lonji; Driver, C; Jones, AT; Swai, H; Verschoor, JA (2008-06)
    The cell wall envelope of Mycobacterium tuberculosis contains unique high molecular weight lipids. Of these, the most abundant are mycolic acids, an extended family of long 2-alkyl 3-hydroxyl fatty acids, typically 70-90 ...
  • Benadie, Y; Semete, B; Venter, L; Kalombo, Lonji; Driver, C; Jones, AT; Swai, H; Verschoor, JA (CSIR, 2008-11)
    The objective of this project was to explore the encapsulation of mycolic acids into vehicles other than liposomes for delivery into macrophages and addressing the challenges of low solubility. As vehicles nanoparticles ...
  • Hayeshi, R; Semete, B; Kalombo, Lonji; Katata, L; Lemmer, Yolandy; Melariri, P; Nyamboli, B; Swai, H (Springer-Verlag, 2012)
    Nanotechnology is a multidisciplinary field covering the design, manipulation, characterisation, production and application of structures, devices and systems at nanometer scale (1–500-nm-size range) which, at this size ...
  • Semete, B; Kalombo, Lonji; Chelule, P; Benadie, Y; Booysen, L; Katata, L; Naidoo, S; Swai, H (CSIR, 2008-11)
    Current therapeutic management of tuberculosis is inadequate due to non-compliance, lengthy course of treatment and drug- related side effects. In order to address these setbacks, the authors are developing a nanotechnology ...
  • Semete, B; Kalombo, Lonji; Katata, L; Chelule, P; Booysen, L; Lemmer, Yolandy; Naidoo, S; Ramalapa, B; Hayeshi, R; Swai, HS (Taylor & Francis, 2012-03)
    Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single ...
  • Hayeshi, R; Semete, B; Kalombo, Lonji; Lemmer, Yolandy; Katata, L; Swai, H (CRC Netbase, 2013-11)
    Nanotechnology is a multidisciplinary field that encompasses the design, manipulation, characterization, production, and application of structures, devices, and systems at the nanometer scale range (~1–500 nm), which present ...
  • Lemmer, Yolandy; Semete, B; Booysen, L; Kalombo, Lonji; Katata, L; Jones, AT; Alexander, C; Khati, M; Swai, HS; Verschoor, JA (2010-06)
    South Africa currently has the highest incidence of TB per 100000 (358 per 100000) people in the world. In 2007 alone 112000 people died of TB in South Africa, of which 94 000 (72%) were co-infected with HIV. Although TB ...